189 related articles for article (PubMed ID: 37783294)
1. Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials.
Housini M; Dariya B; Ahmed N; Stevens A; Fiadjoe H; Nagaraju GP; Basha R
Gene; 2024 Jan; 892():147857. PubMed ID: 37783294
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways.
Postwala H; Shah Y; Parekh PS; Chorawala MR
Med Oncol; 2023 Oct; 40(11):334. PubMed ID: 37855910
[TBL] [Abstract][Full Text] [Related]
3. Role of Regulatory Oncogenic or Tumor Suppressor miRNAs of PI3K/AKT Signaling Axis in the Pathogenesis of Colorectal Cancer.
Soleimani A; Rahmani F; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
Curr Pharm Des; 2018; 24(39):4605-4610. PubMed ID: 30636581
[TBL] [Abstract][Full Text] [Related]
4. LncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathway.
Wang Y; Kuang H; Xue J; Liao L; Yin F; Zhou X
Biomed Pharmacother; 2017 Sep; 93():1230-1237. PubMed ID: 28738539
[TBL] [Abstract][Full Text] [Related]
5. COPS5 and LASP1 synergistically interact to downregulate 14-3-3σ expression and promote colorectal cancer progression via activating PI3K/AKT pathway.
Zhou R; Shao Z; Liu J; Zhan W; Gao Q; Pan Z; Wu L; Xu L; Ding Y; Zhao L
Int J Cancer; 2018 May; 142(9):1853-1864. PubMed ID: 29226323
[TBL] [Abstract][Full Text] [Related]
6. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway.
Yin F; Huang X; Xuan Y
Dis Markers; 2021; 2021():9950663. PubMed ID: 34512817
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Stratification in Colorectal Cancer: MicroRNAs.
Fadaka AO; Pretorius A; Klein A
Cancer Control; 2019; 26(1):1073274819862784. PubMed ID: 31431043
[TBL] [Abstract][Full Text] [Related]
8. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
[No Abstract] [Full Text] [Related]
9. MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer.
Moridikia A; Mirzaei H; Sahebkar A; Salimian J
J Cell Physiol; 2018 Feb; 233(2):901-913. PubMed ID: 28092102
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.
To KK; Tong CW; Wu M; Cho WC
World J Gastroenterol; 2018 Jul; 24(27):2949-2973. PubMed ID: 30038463
[TBL] [Abstract][Full Text] [Related]
11. LncRNAs in colorectal cancer: Biomarkers to therapeutic targets.
Chen LJ; Chen X; Niu XH; Peng XF
Clin Chim Acta; 2023 Mar; 543():117305. PubMed ID: 36966964
[TBL] [Abstract][Full Text] [Related]
12. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challenges.
Das V; Kalita J; Pal M
Biomed Pharmacother; 2017 Mar; 87():8-19. PubMed ID: 28040600
[TBL] [Abstract][Full Text] [Related]
13. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
[TBL] [Abstract][Full Text] [Related]
14. Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review).
Ahmad R; Singh JK; Wunnava A; Al-Obeed O; Abdulla M; Srivastava SK
Int J Mol Med; 2021 Mar; 47(3):. PubMed ID: 33655327
[TBL] [Abstract][Full Text] [Related]
15. TGM3 functions as a tumor suppressor by repressing epithelial‑to‑mesenchymal transition and the PI3K/AKT signaling pathway in colorectal cancer.
Feng Y; Ji D; Huang Y; Ji B; Zhang Y; Li J; Peng W; Zhang C; Zhang D; Sun Y; Xu Z
Oncol Rep; 2020 Mar; 43(3):864-876. PubMed ID: 32020212
[TBL] [Abstract][Full Text] [Related]
16. Proteogenomic biomarkers in colorectal cancers: clinical applications.
Binetti M; Lauro A; Vaccari S; Cervellera M; Tonini V
Expert Rev Proteomics; 2020 May; 17(5):355-363. PubMed ID: 32536221
[TBL] [Abstract][Full Text] [Related]
17. Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.
Rahman MR; Islam T; Gov E; Turanli B; Gulfidan G; Shahjaman M; Banu NA; Mollah MNH; Arga KY; Moni MA
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30658502
[TBL] [Abstract][Full Text] [Related]
18. microRNAs: Small molecules with a large impact on colorectal cancer.
Moazzendizaji S; Sevbitov A; Ezzatifar F; Jalili HR; Aalii M; Hemmatzadeh M; Aslani S; Gholizadeh Navashenaq J; Safari R; Hosseinzadeh R; Rahmany MR; Mohammadi H
Biotechnol Appl Biochem; 2022 Oct; 69(5):1893-1908. PubMed ID: 34550619
[TBL] [Abstract][Full Text] [Related]
19. NAT1 is a critical prognostic biomarker and inhibits proliferation of colorectal cancer through modulation of PI3K/Akt/mTOR.
Cai J; Sun H; Chen L; Xie M; Zhuang J; Gao L; Wei XX
Future Oncol; 2021 Jul; 17(19):2489-2498. PubMed ID: 33906370
[TBL] [Abstract][Full Text] [Related]
20. MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling.
Chen X; Wang W; Li Y; Huo Y; Zhang H; Feng F; Xi W; Zhang T; Gao J; Yang F; Chen S; Yang A; Wang T
J Exp Clin Cancer Res; 2021 Oct; 40(1):341. PubMed ID: 34706761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
